Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 5/20 | 0.44 |
| ▸ | JAK1 | P23458 | 5/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 13/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ULK1 | O75385 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22453882 | 0.91 | LRRK2 (0.55) | LRRK2 | |
| SCHEMBL22445853 | 0.89 | JAK2 (0.43) | JAK2JAK1LRRK2KDM4EALDH1A1 | |
| SCHEMBL22445863 | 0.86 | LRRK2 (0.58) | JAK2JAK1LRRK2 | |
| SCHEMBL22445917 | 0.85 | ULK1 (0.48) | JAK2JAK1LRRK2RAB9AULK1 | |
| SCHEMBL22445869 | 0.84 | JAK2 (0.41) | JAK2JAK1LRRK2ULK1 | |
| SCHEMBL22445924 | 0.83 | LRRK2 (0.59) | JAK2JAK1LRRK2 | |
| SCHEMBL22445882 | 0.82 | LRRK2 (0.45) | JAK2JAK1LRRK2KDM4EALDH1A1 | |
| SCHEMBL22445968 | 0.81 | RAB9A (0.47) | JAK2JAK1LRRK2KDM4EALDH1A1 | |
| SCHEMBL22445920 | 0.79 | RAB9A (0.48) | JAK2JAK1LRRK2KDM4EALDH1A1 | |
| SCHEMBL22445940 | 0.79 | LRRK2 (0.43) | JAK2JAK1LRRK2ULK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020191261-A1 | INDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2020-09-24 | — | — | WO | claimed |
| US-20220162192-A1 | INDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2022-05-26 | — | — | US | disclosed |
| WO-2020191261-A1 | INDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020191261-A1 | INDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162192-A1 | INDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | JAK2 2201/4885JAK1 1985/4885LRRK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.